<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02414828</url>
  </required_header>
  <id_info>
    <org_study_id>C-010-402</org_study_id>
    <nct_id>NCT02414828</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB</brief_title>
  <acronym>C-010-402</acronym>
  <official_title>A Phase II Double-Blind, Randomized, Placebo-controlled, Dose Escalation Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aeras</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Crucell Holland BV</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aeras</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a double-blind, randomized, placebo-controlled dose-escalation study in adults
      recently treated for pulmonary TB. The dose of AERAS-402 increased in successive dose groups.
      Enrollment into a dose group was sequential. Enrollees were stratified based on time from the
      start of TB treatment. The &quot;on-TB-treatment&quot; stratum started TB treatment between 1 and 4
      months (30 to 120 calendar days) prior to Study Day 0. The &quot;post-TB-treatment&quot; stratum
      started TB treatment at least 12 months (360 calendar days) prior to Study Day 0. Subjects
      were randomized to receive a placebo or AERAS-402 vaccine. In Dose Groups 1 and 2, subjects
      were randomized to receive a single injection of AERAS-402 or placebo. Dose Group 3 subjects
      were randomized to receive two injections on study day 0 and study day 42 of AERAS-402 or
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A total of 72 subjects were randomized into the study. Subjects were stratified, based on
      time from the start of TB treatment, into the 'on-TB-treatment' stratum (TB treatment started
      between 1 and 4 months prior to Study Day 0) or the 'post-TB-treatment' stratum (TB treatment
      started at least 12 months before Study Day 0). In the on-TB-treatment stratum, 36 subjects
      were randomized to receive AERAS-402 or placebo as follows: 1 or 2 doses of placebo (N=5); 1
      dose of AERAS-402 at 3 x 10^8 vp (N=5) or 3 x 10^9 vp (N=10), or 2 doses of AERAS-402 at 3 x
      10^10 vp (N=16). In the post-TB-treatment stratum, 36 subjects were randomized to receive
      AERAS-402 or placebo as follows: 1 or 2 doses of placebo (N=6); 1 dose of AERAS-402 at 3 x
      10^8 vp (N=5) or 3 x 109 vp (N=10), or 2 doses of AERAS-402 at 3 x 10^10 vp (N=15).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Solicited and Unsolicited AEs</measure>
    <time_frame>182 days</time_frame>
    <description>All adverse events will be summarized to examine the relationship between dose levels including number (percentage) of solicited and unsolicited adverse events (AEs), and number (percentage) of subjects with newly abnormal post-vaccination laboratory values based on predefined toxicity criteria.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Expiratory Volume in One Second (FEV1)</measure>
    <time_frame>182 days</time_frame>
    <description>Maximum number of subjects with deterioration &gt;10% from baseline, at any time point. in forced expiratory volume in one second (FEV1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Forced Vital Capacity (FVC)</measure>
    <time_frame>182 days</time_frame>
    <description>Maximum number of subjects with deterioration &gt;10% from baseline, at any time point, in forced vital capacity (FVC)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</measure>
    <time_frame>182 Days</time_frame>
    <description>Maximum number of subjects with deterioration &gt;15% from baseline, at any time point, in diffusing capacity of the lung for carbon monoxide (DLCO)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the &quot;on TB Treatment&quot; Stratum</measure>
    <time_frame>42 days post dose</time_frame>
    <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the &quot;on TB Treatment&quot; Stratum</measure>
    <time_frame>42 days post dose</time_frame>
    <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the &quot;Post TB Treatment&quot; Stratum</measure>
    <time_frame>42 days post dose</time_frame>
    <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the &quot;Post TB Treatment&quot; Stratum</measure>
    <time_frame>42 days post dose</time_frame>
    <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo control: 1.0 mL sterile buffer containing 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AERAS-402 3 x 10^8 vp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AERAS-402: 1.0 mL containing 3 x 10^8 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AERAS-402 3 x 10^9 vp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AERAS-402: 1.0 mL containing 3 x 10^9 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AERAS-402 3 x 10^10 vp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AERAS-402: 1.0 mL containing 3 x 10^10 vp/mL suspended in 20 mM Tris buffer, 2 mM MgCl2, 25 mM NaCl, 10% w/v sucrose, 0.02% w/v PS-80 (polysorbate-80, non animal source) and water.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sterile buffer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AERAS-402 3 x 10^8 vp</intervention_name>
    <description>AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0</description>
    <arm_group_label>AERAS-402 3 x 10^8 vp</arm_group_label>
    <other_name>AERAS-402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AERAS-402 3 x 10^9 vp</intervention_name>
    <description>AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0</description>
    <arm_group_label>AERAS-402 3 x 10^9 vp</arm_group_label>
    <other_name>AERAS-402</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>AERAS-402 3 x 10^10 vp</intervention_name>
    <description>AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.</description>
    <arm_group_label>AERAS-402 3 x 10^10 vp</arm_group_label>
    <other_name>AERAS-402</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is male or female.

          2. Is age 18 through 45 years on Study Day 0.

          3. Has completed the written informed consent process.

          4. Has a history of pulmonary tuberculosis diagnosed by either a sputum smear positive
             for acid-fast bacilli (AFB) or a sputum culture positive for Mtb.

          5. Has initiated effective chemotherapy for tuberculosis between one month (30 days) and
             four months (120 days) before Study Day 0, with improvement in clinical signs and/or
             symptoms of disease,

             OR:

             has initiated effective chemotherapy for tuberculosis at least 12 months (360 days)
             before Study Day 0, and is considered cured.

          6. For subjects currently receiving chemotherapy for tuberculosis they must have been
             fully compliant with previously prescribed tuberculosis therapy and agree to complete
             currently prescribed tuberculosis therapy.

          7. Agrees to avoid elective surgery for the full duration of the study.

          8. For female subjects: agrees to avoid pregnancy for the full duration of the study.

          9. Agrees to stay in contact with the study site for the full duration of the study,
             providing updated contact information as necessary, and has no current plans to move
             from the study area during the duration of the study.

         10. Has completed simultaneous enrollment in Aeras Vaccine Development Registry Protocol.

        Exclusion Criteria:

          1. Fever ≥37.5°C.

          2. Evidence of a new acute illness that may compromise the safety of the subject in the
             study.

          3. Evidence of any significant active infection other than tuberculosis.

          4. Evidence of central nervous system tuberculosis or pleural tuberculosis.

          5. Previous medical history that may compromise the safety of the subject in the study,
             including but not limited to: severe impairment of pulmonary function from
             tuberculosis infection or other pulmonary disease; chronic illness with signs of
             cardiac or renal failure; suspected progressive neurological disease; or uncontrolled
             epilepsy or infantile spasms.

          6. Evidence of any systemic disease or any acute or chronic illness that may interfere
             with the evaluation of the safety of the vaccine.

          7. History or laboratory evidence of any past, present or future possible
             immunodeficiency state, including but not limited to any laboratory indication of
             HIV-1 infection.

          8. History of allergic disease or reactions likely to be exacerbated by any component of
             the study vaccine.

          9. Received any investigational drug therapy or vaccine within 182 days before the first
             dose of study vaccine in this protocol.

         10. Received any adenovirus-based vaccine previously.

         11. For female subjects: Currently pregnant, lactating/nursing, or a positive serum or
             urine βhCG

         12. Severe anemia, defined as a hemoglobin less than 10 g/dL or a hematocrit less than 30
             percent.

         13. Urine toxicology screen positive for opiates, cocaine, or amphetamines.

         14. Anal intercourse with another man at least one time (with or without condoms).

         15. Exchange of goods, money, services or drugs for sex.

         16. Use of intravenous drugs.

         17. Sexual intercourse or genital contact within the last 12 months with a known HIV
             positive individual.

         18. Vaginal intercourse within the last 12 months without use of a condom with a known
             user of intravenous drugs.

         19. Oral to genital contact within the last 12 months with a known user of intravenous
             drugs.

         20. Vaginal intercourse within the last 12 months without use of a condom with an
             individual known to have more than one sex partner.

         21. Oral to genital contact within the last 12 months with an individual known to have
             more than one sex partner.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Bateman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cape Town Lung Institute Pty (Ltd)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cape Town Lung Institute Pty (Ltd)</name>
      <address>
        <city>Cape Town</city>
        <state>Mowbray</state>
        <zip>7700</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>South Africa</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2015</study_first_submitted>
  <study_first_submitted_qc>April 10, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2015</study_first_posted>
  <results_first_submitted>March 4, 2016</results_first_submitted>
  <results_first_submitted_qc>April 1, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 4, 2016</results_first_posted>
  <last_update_submitted>April 1, 2016</last_update_submitted>
  <last_update_submitted_qc>April 1, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 4, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Sterile buffer, Intramuscular (IM)</description>
        </group>
        <group group_id="P2">
          <title>AERAS-402 3 x 10^8 vp</title>
          <description>AERAS-402, 1 x IM, study day 0</description>
        </group>
        <group group_id="P3">
          <title>AERAS-402 3 x 10^9 vp</title>
          <description>AERAS-402, 1 x IM, study day 0</description>
        </group>
        <group group_id="P4">
          <title>AERAS-402 3 x 10^10 vp</title>
          <description>AERAS-402, 2 x IM, study days 0 and 42</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="31"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Sterile buffer, Intramuscular (IM)</description>
        </group>
        <group group_id="B2">
          <title>AERAS-402 3 x 10^8 vp</title>
          <description>AERAS-402, 1 x IM, study day 0</description>
        </group>
        <group group_id="B3">
          <title>AERAS-402 3 x 10^9 vp</title>
          <description>AERAS-402, 1 x IM, study day 0</description>
        </group>
        <group group_id="B4">
          <title>AERAS-402 3 x 10^10 vp</title>
          <description>AERAS-402, 2 x IM, study days 0 and 42</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="10"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="31"/>
            <count group_id="B5" value="72"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>18-30 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>31-40 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>41-45 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Coloured</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>TB Treatment Status</title>
          <description>&quot;On TB Treatment&quot; stratum started TB treatment between 1 and 4 months prior to Study Day 0. The &quot;Post TB Treatment&quot; stratum started TB treatment at least 12 months prior to Study Day 0</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>On TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="16"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>History of Smoking</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes - History of smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="20"/>
                    <measurement group_id="B5" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No - History of Smoking</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Solicited and Unsolicited AEs</title>
        <description>All adverse events will be summarized to examine the relationship between dose levels including number (percentage) of solicited and unsolicited adverse events (AEs), and number (percentage) of subjects with newly abnormal post-vaccination laboratory values based on predefined toxicity criteria.</description>
        <time_frame>182 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile Buffer, Intramuscular (IM)</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Solicited and Unsolicited AEs</title>
          <description>All adverse events will be summarized to examine the relationship between dose levels including number (percentage) of solicited and unsolicited adverse events (AEs), and number (percentage) of subjects with newly abnormal post-vaccination laboratory values based on predefined toxicity criteria.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="31"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the &quot;on TB Treatment&quot; Stratum</title>
        <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
        <time_frame>42 days post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile buffer, IM</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the &quot;on TB Treatment&quot; Stratum</title>
          <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
          <units>percentage of T Cell response</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On TB Treatment CD4 Ag85A Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.168"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.062"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 Ag85A Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.056" lower_limit="0.025" upper_limit="0.112"/>
                    <measurement group_id="O3" value="0.057" lower_limit="0.025" upper_limit="0.176"/>
                    <measurement group_id="O4" value="0.061" lower_limit="0.025" upper_limit="0.121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 Ag85A Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.072" lower_limit="0.025" upper_limit="0.228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 Ag85B Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.097"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.085"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.093"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 Ag85B Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.112"/>
                    <measurement group_id="O3" value="0.052" lower_limit="0.025" upper_limit="0.175"/>
                    <measurement group_id="O4" value="0.082" lower_limit="0.025" upper_limit="0.160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 Ag85B Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.233" lower_limit="0.164" upper_limit="0.303"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.489" lower_limit="0.153" upper_limit="0.789"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 TB10.4 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.068" lower_limit="0.025" upper_limit="0.143"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.063" lower_limit="0.025" upper_limit="0.115"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 TB10.4 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.223"/>
                    <measurement group_id="O3" value="0.053" lower_limit="0.025" upper_limit="0.064"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD4 TB10.4 Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.120" lower_limit="0.025" upper_limit="0.216"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.043" lower_limit="0.025" upper_limit="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Forced Expiratory Volume in One Second (FEV1)</title>
        <description>Maximum number of subjects with deterioration &gt;10% from baseline, at any time point. in forced expiratory volume in one second (FEV1)</description>
        <time_frame>182 days</time_frame>
        <population>Subjects who were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile buffer, IM</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in One Second (FEV1)</title>
          <description>Maximum number of subjects with deterioration &gt;10% from baseline, at any time point. in forced expiratory volume in one second (FEV1)</description>
          <population>Subjects who were evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Forced Vital Capacity (FVC)</title>
        <description>Maximum number of subjects with deterioration &gt;10% from baseline, at any time point, in forced vital capacity (FVC)</description>
        <time_frame>182 days</time_frame>
        <population>Subjects who were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile buffer, IM</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Vital Capacity (FVC)</title>
          <description>Maximum number of subjects with deterioration &gt;10% from baseline, at any time point, in forced vital capacity (FVC)</description>
          <population>Subjects who were evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</title>
        <description>Maximum number of subjects with deterioration &gt;15% from baseline, at any time point, in diffusing capacity of the lung for carbon monoxide (DLCO)</description>
        <time_frame>182 Days</time_frame>
        <population>Subjects who were evaluated.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile buffer, IM</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Diffusing Capacity of the Lung for Carbon Monoxide (DLCO)</title>
          <description>Maximum number of subjects with deterioration &gt;15% from baseline, at any time point, in diffusing capacity of the lung for carbon monoxide (DLCO)</description>
          <population>Subjects who were evaluated.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="20"/>
                <count group_id="O4" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the &quot;on TB Treatment&quot; Stratum</title>
        <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
        <time_frame>42 days post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile buffer, IM</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the &quot;on TB Treatment&quot; Stratum</title>
          <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
          <units>percentage of T Cell response</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On TB Treatment CD8 Ag85A Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 Ag85A Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.070"/>
                    <measurement group_id="O2" value="0.085" lower_limit="0.025" upper_limit="0.258"/>
                    <measurement group_id="O3" value="0.301" lower_limit="0.081" upper_limit="2.049"/>
                    <measurement group_id="O4" value="0.076" lower_limit="0.025" upper_limit="0.584"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 Ag85A Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.169" lower_limit="0.025" upper_limit="2.340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 Ag85B Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.066"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.481"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 Ag85B Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.083"/>
                    <measurement group_id="O2" value="0.089" lower_limit="0.025" upper_limit="0.223"/>
                    <measurement group_id="O3" value="0.310" lower_limit="0.104" upper_limit="2.352"/>
                    <measurement group_id="O4" value="0.125" lower_limit="0.058" upper_limit="0.332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 Ag85B Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" lower_limit="0.025" upper_limit="0.135"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.571" lower_limit="0.364" upper_limit="2.239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 TB10.4 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 TB10.4 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.068" lower_limit="0.025" upper_limit="0.078"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.533"/>
                    <measurement group_id="O4" value="0.223" lower_limit="0.025" upper_limit="0.505"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On TB Treatment CD8 TB10.4 Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.079" lower_limit="0.025" upper_limit="0.315"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the &quot;Post TB Treatment&quot; Stratum</title>
        <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
        <time_frame>42 days post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile buffer, IM</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of AERAS-402 Based on the Percentage of CD4 Cells of Participants in the &quot;Post TB Treatment&quot; Stratum</title>
          <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
          <units>percentage of T Cell response</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post TB Treatment CD4 Ag85A Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.067"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.060"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 Ag85A Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.056" lower_limit="0.025" upper_limit="0.092"/>
                    <measurement group_id="O3" value="0.089" lower_limit="0.025" upper_limit="0.148"/>
                    <measurement group_id="O4" value="0.057" lower_limit="0.025" upper_limit="0.130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 Ag85A Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.091" lower_limit="0.068" upper_limit="0.127"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 Ag85B Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.290"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.057"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.064"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.059"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 Ag85B Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.237"/>
                    <measurement group_id="O2" value="0.038" lower_limit="0.025" upper_limit="0.063"/>
                    <measurement group_id="O3" value="0.076" lower_limit="0.025" upper_limit="0.146"/>
                    <measurement group_id="O4" value="0.105" lower_limit="0.025" upper_limit="0.140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 Ag85B Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.487" lower_limit="0.025" upper_limit="0.657"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.547" lower_limit="0.360" upper_limit="0.849"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 TB10.4 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.175"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.093"/>
                    <measurement group_id="O3" value="0.040" lower_limit="0.025" upper_limit="0.074"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 TB10.4 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.163"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.089" lower_limit="0.025" upper_limit="0.174"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.099"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD4 TB10.4 Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.069"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the &quot;Post TB Treatment&quot; Stratum</title>
        <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
        <time_frame>42 days post dose</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Sterile buffer, IM</description>
          </group>
          <group group_id="O2">
            <title>AERAS-402 3 x 10^8 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O3">
            <title>AERAS-402 3 x 10^9 vp</title>
            <description>AERAS-402, 1 x IM, study day 0</description>
          </group>
          <group group_id="O4">
            <title>AERAS-402 3 x 10^10 vp</title>
            <description>AERAS-402, 2 x IM, study days 0 and 42</description>
          </group>
        </group_list>
        <measure>
          <title>Immunogenicity of AERAS-402 Based on the Percentage of CD8 Cells of Participants in the &quot;Post TB Treatment&quot; Stratum</title>
          <description>Assessment of immune response to AERAS-402 was based on the percentage of CD4 and CD8 T cells producing any combination of three cytokines (IFN-γ, TNF-α, and/or IL-2) following stimulation with mycobacterial peptide pools derived from and representing the entire amino acid sequences of mycobacterial antigens Ag85A, Ag85B, and TB10.4. Responses were measured by the intracellular cytokine staining (ICS) assay using flow cytometry.</description>
          <units>percentage of T Cell response</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Post TB Treatment CD8 Ag85A Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.057"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 Ag85A Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="0.584" lower_limit="0.025" upper_limit="2.205"/>
                    <measurement group_id="O3" value="0.083" lower_limit="0.025" upper_limit="2.037"/>
                    <measurement group_id="O4" value="0.054" lower_limit="0.025" upper_limit="0.279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 Ag85A Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.400" lower_limit="0.125" upper_limit="0.710"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 Ag85B Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.228"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 Ag85B Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.193"/>
                    <measurement group_id="O2" value="0.439" lower_limit="0.025" upper_limit="1.830"/>
                    <measurement group_id="O3" value="0.206" lower_limit="0.025" upper_limit="1.945"/>
                    <measurement group_id="O4" value="0.169" lower_limit="0.025" upper_limit="0.475"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 Ag85B Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.109" lower_limit="0.025" upper_limit="0.393"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.673" lower_limit="0.338" upper_limit="1.206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 TB10.4 Day 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.161"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 TB10.4 Day 42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.094"/>
                    <measurement group_id="O2" value="0.025" lower_limit="0.025" upper_limit="0.417"/>
                    <measurement group_id="O3" value="0.025" lower_limit="0.025" upper_limit="0.285"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.025" upper_limit="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post TB Treatment CD8 TB10.4 Day 84</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.025" lower_limit="0.025" upper_limit="0.025"/>
                    <measurement group_id="O2" value="NA">No second dose given</measurement>
                    <measurement group_id="O3" value="NA">No second dose given</measurement>
                    <measurement group_id="O4" value="0.104" lower_limit="0.025" upper_limit="0.251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Sterile buffer, Intramuscular (IM)</description>
        </group>
        <group group_id="E2">
          <title>AERAS-402 3 x 10^8 vp</title>
          <description>AERAS-402, 1 x IM, study day 0</description>
        </group>
        <group group_id="E3">
          <title>AERAS-402 3 x 10^9 vp</title>
          <description>AERAS-402, 1 x IM, study day 0</description>
        </group>
        <group group_id="E4">
          <title>AERAS-402 3 x 10^10 vp</title>
          <description>AERAS-402, 2 x IM, study days 0 and 42</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (11.0)">Bronchioloalveolar carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="10"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Microcytosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E4" events="18" subjects_affected="15" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E4" events="32" subjects_affected="20" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vessel puncture site haematoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood pressure diastolic increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic decreased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="11" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Carbon monoxide diffusing capacity decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Crystal urine present</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>False positive tuberculosis test</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Glucose urine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" events="12" subjects_affected="9" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Heart rate decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="8" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Protein urine</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="11"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="10"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E4" events="20" subjects_affected="14" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Red blood cell hypochromic morphology present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Red blood cell morphology abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Red blood cells urine</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E4" events="15" subjects_affected="10" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Vital capacity decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="9" subjects_affected="6" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Weight gain poor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="10" subjects_affected="9" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="6" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="31"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Physical assault</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Labile blood pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="10"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="31"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Ann Ginsberg, Chief Medical Officer</name_or_title>
      <organization>Aeras</organization>
      <phone>301-547-2912</phone>
      <email>aginsberg@aeras.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

